JP2019510075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510075A5 JP2019510075A5 JP2018561462A JP2018561462A JP2019510075A5 JP 2019510075 A5 JP2019510075 A5 JP 2019510075A5 JP 2018561462 A JP2018561462 A JP 2018561462A JP 2018561462 A JP2018561462 A JP 2018561462A JP 2019510075 A5 JP2019510075 A5 JP 2019510075A5
- Authority
- JP
- Japan
- Prior art keywords
- hepatocellular carcinoma
- pharmaceutical composition
- preventing
- treating
- advanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 10
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000002962 histologic effect Effects 0.000 claims 1
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160017187A KR101662975B1 (ko) | 2016-02-15 | 2016-02-15 | 간암 치료 또는 예방용 조성물 |
| KR10-2016-0017187 | 2016-02-15 | ||
| PCT/KR2017/001575 WO2017142283A1 (ko) | 2016-02-15 | 2017-02-14 | 간암 치료 또는 예방용 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510075A JP2019510075A (ja) | 2019-04-11 |
| JP2019510075A5 true JP2019510075A5 (enExample) | 2020-02-13 |
| JP6871638B2 JP6871638B2 (ja) | 2021-05-12 |
Family
ID=57164552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561462A Active JP6871638B2 (ja) | 2016-02-15 | 2017-02-14 | 肝癌の治療または予防用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10463669B2 (enExample) |
| JP (1) | JP6871638B2 (enExample) |
| KR (1) | KR101662975B1 (enExample) |
| CN (1) | CN109069513B (enExample) |
| WO (1) | WO2017142283A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101662975B1 (ko) * | 2016-02-15 | 2016-10-06 | 서울대학교산학협력단 | 간암 치료 또는 예방용 조성물 |
| WO2019121872A1 (en) * | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of liver cancer |
| CN110665007A (zh) * | 2019-09-19 | 2020-01-10 | 邦世（苏州）生物医药科技有限公司 | 一种治疗癌症用组合药物及其用途 |
| KR102699871B1 (ko) | 2021-04-29 | 2024-08-29 | 주식회사 서지넥스 | 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도 |
| KR20230112770A (ko) | 2022-01-20 | 2023-07-28 | 가톨릭대학교 산학협력단 | 항섬유화 억제용 조성물 |
| CN114796482A (zh) * | 2022-05-31 | 2022-07-29 | 江苏省人民医院（南京医科大学第一附属医院） | gsk3β抑制剂在制备提高抗肝细胞肝癌疗效的药物中的应用 |
| KR20250044972A (ko) | 2023-09-25 | 2025-04-01 | 주식회사 마스터메디텍 | 이델라리십 함유 경구투여용 고형제제 및 그 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2421536B1 (en) * | 2009-04-20 | 2015-08-26 | Gilead Calistoga LLC | Methods of treatment for solid tumors |
| US8691829B2 (en) * | 2009-07-21 | 2014-04-08 | Gilead Calistoga Llc | Treatment of liver disorders with PI3K inhibitors |
| WO2013082540A1 (en) * | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| WO2014046617A1 (en) * | 2012-09-19 | 2014-03-27 | Agency For Science, Technology And Research | Compositions and methods for treating cancer |
| KR101418161B1 (ko) * | 2012-09-26 | 2014-07-09 | 부경대학교 산학협력단 | 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물 |
| CA2915250A1 (en) * | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Cell stabilization |
| CN104817559B (zh) * | 2014-01-30 | 2021-05-25 | 苏州泽璟生物制药股份有限公司 | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 |
| WO2016097314A1 (en) * | 2014-12-19 | 2016-06-23 | Sandoz Ag | Amorphous and crystalline forms of idelalisib and process for forming the same |
| KR101662975B1 (ko) * | 2016-02-15 | 2016-10-06 | 서울대학교산학협력단 | 간암 치료 또는 예방용 조성물 |
-
2016
- 2016-02-15 KR KR1020160017187A patent/KR101662975B1/ko active Active
-
2017
- 2017-02-14 CN CN201780023517.4A patent/CN109069513B/zh active Active
- 2017-02-14 US US15/998,556 patent/US10463669B2/en active Active
- 2017-02-14 JP JP2018561462A patent/JP6871638B2/ja active Active
- 2017-02-14 WO PCT/KR2017/001575 patent/WO2017142283A1/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510075A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| TN2017000119A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| FI3618875T3 (fi) | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito | |
| TN2017000468A1 (en) | TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS. | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| MY196243A (en) | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals | |
| JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
| JP2015500225A5 (enExample) | ||
| RU2016131756A (ru) | Применение альфавируса в получении противоопухолевых лекарственных средств | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| RU2018113718A (ru) | Новые соединения | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| BR112016017781A2 (pt) | Compostos de pirazolona e usos dos mesmos | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| HK1232227A1 (zh) | 作为pi3k抑制剂的喹嗪酮衍生物 | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| EA201990311A1 (ru) | АНТИМЕТАСТАТИЧЕСКИЕ 2H-СЕЛЕНОФЕН[3,2-h]ХРОМЕНЫ, СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ |